Use of a chemically induced-colon carcinogenesis-prone Apc-mutant rat in a chemotherapeutic bioassay

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Yoshimi, Kazuto ^a   Hashimoto, Takao ^b   Niwa, Yusuke ^b   Hata, Kazuya ^b   Serikawa, Tadao ^a   Tanaka, Takuji ^c   Kuramoto, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Sunplanet Co Ltd   (Japan)

^c Cancer Research and Prevention   (Japan)

Author keywords

5 fluorouracil; Adenomatous polyposis coli; Chemotherapy; Colorectal cancer; Endoscopy; Rat

Indexed keywords

AZOXYMETHANE; FLUOROURACIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER CHEMOTHERAPY; CANCER SIZE; CHEMOTHERAPEUTIC BIOASSAY; COLON CARCINOGENESIS; COLONOSCOPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; HISTOPATHOLOGY; HOMOZYGOTE; KYOTO APC DELTA RAT; MALE; MAXIMUM TOLERATED DOSE; MUTAGENESIS; NONHUMAN; NONSENSE MUTATION; RAT; RAT STRAIN; RETREATMENT; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZOXYMETHANE; COLON; COLONIC NEOPLASMS; DEXTRAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; INJECTIONS, INTRAVENOUS; MALE; MUTATION; RATS; REPRODUCIBILITY OF RESULTS;

EID: 84866885515     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-448     Document Type: Article

References (17)

1. Blumenthal RD, Osorio L, Hayes MK, Horak ID, Hansen HJ, Goldenberg DM. Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother 2005, 54(4):315-327. 10.1007/s00262-004-0597-6, 15592930.
2. Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003, 12(5):391-400. 2797538, 12750232.
3. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002, 86(7):1157-1161. 10.1038/sj.bjc.6600182, 2364169, 11953865.
4. Ding Y, Cravero JD, Adrian K, Grippo P. Modeling pancreatic cancer in vivo: from xenograft and carcinogen-induced systems to genetically engineered mice. Pancreas 2010, 39(3):283-292. 10.1097/MPA.0b013e3181c15619, 20335777.
5. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003, 9(11):4227-4239.
6. Femia AP, Caderni G. Rodent models of colon carcinogenesis for the study of chemopreventive activity of natural products. Planta Med 2008, 74(13):1602-1607. 10.1055/s-2008-1074577, 18604780.
7. Bruce WR. Counterpoint: From animal models to prevention of colon cancer. Criteria for proceeding from preclinical studies and choice of models for prevention studies. Cancer Epidemiol Biomarkers Prev 2003, 12(5):401-404.
8. Reddy BS. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 2004, 44(1):26-35. 10.1002/em.20026, 15199544.
9. Reddy BS, Maeura Y. Tumor promotion by dietary fat in azoxymethane-induced colon carcinogenesis in female F344 rats: influence of amount and source of dietary fat. J Natl Cancer Inst 1984, 72(3):745-750.
10. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003, 94(11):965-973. 10.1111/j.1349-7006.2003.tb01386.x, 14611673.
11. Yoshimi K, Tanaka T, Takizawa A, Kato M, Hirabayashi M, Mashimo T, Serikawa T, Kuramoto T. Enhanced colitis-associated colon carcinogenesis in a novel Apc mutant rat. Cancer Sci 2009, 100(11):2022-2027. 10.1111/j.1349-7006.2009.01287.x, 19694754.
12. Carlsson G, Gullberg B, Hafstrom L. Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 1983, 105(1):20-23. 10.1007/BF00391826, 6833336.
13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
14. Ogawa K, Mukai T, Kawai K, Takamura N, Hanaoka H, Hashimoto K, Shiba K, Mori H, Saji H. Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases. Eur J Nucl Med Mol Imaging 2009, 36(1):115-121. 10.1007/s00259-008-0925-8, 18709369.
15. Thomas DM, Zalcberg JR. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol 1998, 25(11):887-895. 10.1111/j.1440-1681.1998.tb02339.x, 9807659.
16. Cao S, Rustum YM. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 2000, 60(14):3717-3721.
17. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000, 6(4):1322-1327.